Metoprolol Medical Valley (Metoprolol Tartrate)

Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in the heart, preventing adrenaline and noradrenaline from binding. This reduces cyclic AMP formation, leading to slower heart‑node firing, decreased contractility, and lower cardiac output, which together lower blood pressure and heart rate.

The dosage of Metoprolol Medical Valley is individualized by the prescribing clinician based on the specific indication, patient age, renal function, and response to therapy. Only a qualified healthcare professional can determine the appropriate dose and titration schedule.

Safety data for Metoprolol Tartrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metoprolol is a cardio‑selective (β1‑selective) beta‑blocker, offering a favorable profile for patients with respiratory concerns compared with non‑selective agents like propranolol. Its once‑daily dosing and proven efficacy in hypertension, angina, and post‑MI care make it a common choice, though individual response and tolerability guide final selection.

Store Metoprolol Medical Valley at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Metoprolol Medical Valley is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe bradycardia, heart block, profound hypotension, bronchospasm in patients with asthma or COPD, and masking of hypoglycaemia symptoms in diabetic patients. Patients should seek immediate medical attention if they experience fainting, extreme fatigue, or respiratory difficulty.

Metoprolol Medical Valley should be avoided in individuals with known hypersensitivity to metoprolol or any component of the formulation, those with severe sinus bradycardia, second‑ or third‑degree heart block without a pacemaker, and patients with uncompensated heart failure or severe asthma unless a physician determines otherwise.